By Doug Macron
The US Patent and Trademark Office may "very shortly" give notice that it plans to award the country's first patent on an application from the Tuschl-I intellectual property estate, according to court documents filed earlier this month by the Max Planck Institute and Alnylam Pharmaceuticals.
As a result, they have asked for a court order effectively stopping the issuance of the patent until an ongoing lawsuit over the IP can play out.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
